Cargando…

The Efficacy of Combining Antiangiogenic Agents with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review and Meta-Analysis

BACKGROUND: The clinical outcomes of patients with NSCLC who progressed after first-line treatments remain poor. The purpose of this study was to assess the advantage of antiangiogenic therapy plus standard treatment versus standard treatment alone for this population of patients. METHODS: We conduc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheng, Jin, Yang, Yunpeng, Ma, Yuxiang, Yang, Bijun, Zhang, Yaxiong, Kang, Shiyang, Zhou, Ting, Hong, Shaodong, Qin, Tao, Hu, Zhihuang, Fang, Wenfeng, Huang, Yan, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452723/ https://www.ncbi.nlm.nih.gov/pubmed/26034985 http://dx.doi.org/10.1371/journal.pone.0127306

Ejemplares similares

The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment
por: Zhou, Ting, et al.
Publicado: (2015)

Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
por: Zhang, Yaxiong, et al.
Publicado: (2014)

Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses
por: Liang, Wenhua, et al.
Publicado: (2014)

The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer
por: Zhang, Yaxiong, et al.
Publicado: (2015)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
por: Zhou, Yixin, et al.
Publicado: (2018)

Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis
por: Zhang, Yaxiong, et al.
Publicado: (2016)

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma
por: Vo, Kieuhoa T., et al.
Publicado: (2016)

Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy
por: Hu, Zhihuang, et al.
Publicado: (2016)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
por: Chen, Chen, et al.
Publicado: (2020)

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
por: Ulahannan, Susanna V, et al.
Publicado: (2011)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
por: Lee, Min Jeong, et al.
Publicado: (2012)

Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer
por: Zhou, Ting, et al.
Publicado: (2015)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Zhonghan, et al.
Publicado: (2020)

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
por: Fang, Wenfeng, et al.
Publicado: (2014)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Editorial: Are natural products, used as antitumoral/antiangiogenic agents, less toxic than synthetic conventional chemotherapy?
por: Nunez, Cecilia Veronica, et al.
Publicado: (2022)

Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis
por: Yi, SuYi, et al.
Publicado: (2017)

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
por: Sheng, Jin, et al.
Publicado: (2016)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy
por: Kim, Se Hyun, et al.
Publicado: (2017)

Erratum: Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
por: Sheng, Jin, et al.
Publicado: (2016)

The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy
por: Wang, Tian, et al.
Publicado: (2022)

Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms
por: Shen, Jiayi, et al.
Publicado: (2020)

A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis
por: Li, Yimin, et al.
Publicado: (2020)

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
por: Pang, Lan-Lan, et al.
Publicado: (2023)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy
por: Yonucu, Sirin, et al.
Publicado: (2017)

Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells
por: Winter, Ursula, et al.
Publicado: (2016)

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
por: Hong, Shaodong, et al.
Publicado: (2014)

PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
por: Fang, Wenfeng, et al.
Publicado: (2015)

Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
por: Dama, Paola, et al.
Publicado: (2019)

Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes?
por: Zhang, Yaxiong, et al.
Publicado: (2019)

Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy
por: Tao, Chang-Juan, et al.
Publicado: (2020)

Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer
por: Ramcharan, K S, et al.
Publicado: (2014)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
por: Xu, Yinghui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d3c5o2mop1se5j3r0nee2dgdgg